ARCE
DEAD

Serial Number

90431302

Owner

ARCE THERAPEUTICS, INC.

Attorney

Zhi Dong

Filing Date

Dec 30, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ARCE Trademark

Serial Number: 90431302

ARCE is a trademark filed by ARCE THERAPEUTICS, INC. on December 30, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ARCE THERAPEUTICS, INC. (7 trademarks)

Taipei City 11492 , TW

Entity Type: 03

Trademark Details

Filing Date

December 30, 2020

Registration Date

Not Registered

Published for Opposition

December 14, 2021

Goods & Services

Biological preparations for medical purposes, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; biological preparations for veterinary purposes for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; biological tissue cultures for medical purposes, namely, human blood samples, human allograft tissues, human umbilical cord blood and human induced pluripotent stem cells (iPSCs) from somatic cells; biological tissue cultures for veterinary purposes, namely, animal blood samples, tumors and allograft tissues; blood for medical purposes; cultures of microorganisms for medical or veterinary use; diagnostic biomarker reagents for medical purposes, namely, chemical and biological reagents for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; pharmaceuticals, namely, drugs for medical purposes, namely, for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; enzymes for medical purposes; enzymes for veterinary purposes; immunostimulants; medicinal infusions for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceuticals, namely, medicines for human purposes, namely, for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceuticals, namely, medicines for veterinary purposes, namely, for veterinary cancers; preparations of microorganisms for medical or veterinary use, namely, cultures of bacteria and viruses for medical or veterinary use; pharmaceutical preparations for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceutical preparations, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; pharmaceuticals, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; pharmaceuticals in the nature of pharmaceutical preparations for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; transplants comprised of living cells, namely, genetically engineered tissues for medical and transplant purposes; genetically engineered cells for medical purposes, specifically for transplantation purposes; vaccines

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 8, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 8, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 22, 2025 EXRA
SOU EXTENSION 5 GRANTED
Apr 22, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 21, 2025 AITU
SOU EXTENSION 5 FILED
Jan 23, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
Jan 23, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 24, 2024 EXRA
SOU EXTENSION 4 GRANTED
Jul 19, 2024 EX4G
SOU EXTENSION 4 FILED
Jul 19, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Jul 19, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 2, 2024 EXRA
SOU EXTENSION 3 GRANTED
Jan 31, 2024 EX3G
SOU EXTENSION 3 FILED
Jan 31, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 31, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 29, 2023 EXRA
SOU EXTENSION 2 GRANTED
Jul 27, 2023 EX2G
SOU EXTENSION 2 FILED
Jul 27, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 27, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 22, 2022 EXRA
SOU EXTENSION 1 GRANTED
Nov 18, 2022 EX1G
SOU EXTENSION 1 FILED
Nov 18, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 18, 2022 EEXT
CORRECTED NOA E-MAILED
Nov 4, 2022 NOAC
DIVISIONAL PROCESSING COMPLETE
Nov 3, 2022 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 2, 2022 AITU
DIVISIONAL REQUEST RECEIVED
Oct 20, 2022 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Oct 20, 2022 ERTD
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 2, 2022 NOAM
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jun 23, 2022 ETOP
EXTENSION OF TIME TO OPPOSE RECEIVED
Jan 7, 2022 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 14, 2021 NPUB
PUBLISHED FOR OPPOSITION
Dec 14, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 24, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 10, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 9, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 8, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 8, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 6, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jul 6, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jul 6, 2021 CNRT
ASSIGNED TO EXAMINER
Jul 1, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 24, 2021 NWOS
NEW APPLICATION ENTERED
Jan 2, 2021 NWAP